G

Galmed Pharmaceuticals Ltd
D

GLMD

2.90000
USD
-0.12
(-3.97%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
0
حجم السوق
4,805,277
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.520
    (-2.99%)
    16.900 USD
    A
    AMRN
    -0.01480
    (-3.17%)
    0.45150 USD
    BGNE
    BGNE
    -3.325
    (-1.85%)
    175.950 USD
    C
    CTMX
    -0.05500
    (-4.91%)
    1.06500 USD
    E
    EGRX
    0
    (0%)
    0.000000 USD
    F
    FGEN
    -0.00410
    (-1.17%)
    0.34690 USD
    J
    JAZZ
    -0.880
    (-0.72%)
    121.710 USD
    JNJ
    JNJ
    -1.660
    (-1.13%)
    144.730 USD
    L
    LIVN
    -2.230
    (-4.47%)
    47.690 USD
    M
    MYOV
    0
    (0%)
    0.000000 USD
    N
    NBRV
    0.04000
    (2.84%)
    1.45000 USD
    R
    RIGL
    -1.410
    (-7.64%)
    17.050 USD
    S
    SSNC
    -2.360
    (-3.10%)
    73.680 USD
    X
    XENE
    -1.890
    (-4.58%)
    39.410 USD
    X
    XNCR
    -1.310
    (-5.24%)
    23.710 USD
    المزيد
الأخبار

العنوان: Galmed Pharmaceuticals Ltd

القطاع: Healthcare
الصناعة: Biotechnology
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIaclinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.